ATARA BIOTHERAPEUTICS, INC. Proceeds from Royalties Received
ATARA BIOTHERAPEUTICS, INC. (ATRA) reported Proceeds from Royalties Received of $31.00 million for the 12-month period ending 2022-12-31, per its 10-K filed 2023-02-08.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromRoyaltiesReceived · last filed 2023-02-08
- ATARA BIOTHERAPEUTICS, INC. proceeds from royalties received for fiscal 2022 was $31.00M.
| Period end | Proceeds from Royalties Received 12 month |
|---|---|
| 2022-12-31 | $31.00M 10-K · filed 2023-02-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Vaxart, Inc. (VXRT) | United States | $0.080B | 3.84 |
| Kalaris Therapeutics, Inc. (KLRS) | United States | $0.073B | -2.19 |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| CHAMPIONS ONCOLOGY, INC. (CSBR) | United States | $0.070B | -68.02 |
| BioStem Technologies, Inc. (BSEM) | United States | $0.069B | |
| Eloxx Pharmaceuticals, Inc. (ELOX) | United States | $0.065B | |
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |